AGM Presentation
Released
Released
Announcement PDF
1800 519 711 | ltrpharma.com | investors@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
2026 Annual General Meeting Presentation
23 October 2026
LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) advises that the Annual General Meeting (“AGM”)
will be held today, Friday, 23 October 2026, at 2:00pm (AEST), at the offices of K&L Gates 16/66 Eagle Street, Bris-
bane City QLD 4000.
Attached is the AGM presentation to be delivered at the 2026 Annual General Meeting
- ENDS -
This announcement has been approved by the Board of Directors.
About LTR Pharma
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant
unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully
commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regu-
latory pathways in the US and other key markets.
LTR’s lead products, SPONTAN®
and ROXUS®
, are fast-acting intranasal sprays for the treatment of erectile dys-
function, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now
advancing OROFLOW®
, a novel intranasal spray under development for the treatment of Oesophageal Motility
Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated,
patient-centric treatments that enhance quality of life.
LTR Pharma Investor Centre
Stay informed with LTR Pharma’s latest announcements and
market updates by visiting our Investor Centre or scan the QR code.
For further information please contact:
Media enquiries Investor enquiries
Haley Chartres Peter McLennan
haley@hck.digital investors@ltrpharma.com
Annual General
Meeting
23 October 2026
AGM Presentation | October 2026
Important Notice and Disclaimer
AGM Presentation | October 2026 2
‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd
(Company or LTP) to provide general information about the Company. The information in this
document is in summary form and should not be relied upon as a complete and accurate
representation of any matters that a reader should consider in evaluating the Company. While
the Company has taken reasonable care in preparing this presentation, no representation is
made as to the accuracy or completeness of the material contained in it.
‣ Not an offer: This presentation is NOT a recommendation, offer or invitation to subscribe for or
purchase LTP securities. This presentation is not exhaustive and does not contain all of the
information a potential investor, or their professional advisers would require, and it does NOT
constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001
(Cth), and has not been, and will not be, lodged with the Australian Securities and Investments
Commission or any other regulatory authority. This presentation should not be distributed,
transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or
viewing of this document would be unlawful under the securities or other laws of that or any
other jurisdiction. In particular, this presentation may not be released to US wire services or
distributed publicly in the United States. This presentation does not constitute an offer to sell, or
a solicitation of an offer to buy any securities in any jurisdiction. Any failure to comply with such
restrictions could constitute a violation of applicable securities laws.
‣ Not financial product advice: You should not act and should refrain from acting in reliance on this
presentation. Nothing contained in this presentation constitutes investment, legal, tax or other
advice. This presentation does not take into account the individual investment objectives, financial
situation and particular needs of potential investors. Before making a decision to invest in the
Company at any time, you should conduct, with the assistance of your broker or other financial or
professional adviser, your own investigation in light of your particular investment needs,
objectives and financial circumstances and perform your own analysis of the Company before
making any investment decision.
‣ Forward looking statements: This presentation contains forward-looking information about the
Company and its operations. In certain cases, forward-looking information may be identified by
such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”,
"expects", "may", “intend”, "shall", "will", or "would". These statements are based on information
currently available to the Company and the Company provides no assurance that actual results
will meet management's expectations. Forward-looking statements are subject to risk factors
associated with the Company’s business, many of which are beyond the control of the Company.
It is believed that the expectations reflected in these statements are reasonable but they may be
affected by a variety of variables and changes in underlying assumptions which could cause actual
results or trends to differ materially from those expressed or implied in such statements. There
can be no assurance that actual outcomes will not differ materially from these statements.
‣ Disclaimer: No representation or warranty, express or implied, is made by the Company that the
material contained in this presentation will be achieved or proved correct. Except for statutory
liability which cannot be excluded, the Company, its directors, officers, and employees expressly
disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material
contained in this presentation and excludes all liability whatsoever (including in negligence) for
any loss or damage which may be suffered by any person as a consequence of any information
in this presentation or any error or omission therefrom. The Company will not update or keep
current the information contained in this presentation or to correct any inaccuracy or omission
which may become apparent, or to furnish any person with any further information. Any opinions
expressed in the presentation are subject to change without notice.
‣ LTR Pharma Limited ACN 644 924 569
‣ No New Material Information: This presentation contains no new material information;
all information has been previously disclosed in the Company's ASX announcements.
FY26 in review
Key milestones, 1 July 2025 to 30 June 2026
Q1 FY26
Jul to Sep 2025
‣ Dr Amy Pearlman and Dr
Andrew Sun join the
Scientific Advisory Board
‣ SPONTAN® Phase I data
published (EJPS)
‣ 18-month shelf life
achieved
‣ 33% interest in LevOmega
Q2 FY26
Oct to Dec 2025
‣ Ethics approval and TGA
clearance for SPONTAN®
Phase II
‣ 1,000 SPONTAN®
prescriptions under the
TGA Special Access Scheme
‣ LevOmega interest
increased to 43%
Q3 FY26
Jan to Mar 2026
‣ Phase II recruitment
commenced and
completed
‣ Phase I data presented at
WMSM 2026, Porto
(podium)
‣ Positive real-world
outcomes in younger men
Q4 FY26
Apr to Jun 2026
‣ Phase II interim data: rapid
onset, supports FDA
pathway
‣ Binding term sheets with
Shed Holdings and Strive
Pharmacy
‣ OROFLOW® study receives
ethics approval
Source: ASX announcements, July 2025 to June 2026; FY26 Annual Report. Conference presentations and media coverage are on the "Making headlines" slide.
AGM Presentation | October 2026
Since year-end
From U.S. agreements to first U.S. prescriptions, July to October 2026
Jul to Sep 2026
‣ JUL Definitive U.S. agreements executed with
Shed Holdings and Strive Pharmacy
‣ AUG 147-patient real-world study: 93%
response in men seeking convenience; 68%
overall
‣ SEP KYZATREX® pilot commercialisation
agreement with Marius Pharmaceuticals
October 2026
October 2026 to date
‣ 1 OCT Final Phase II Clinical Study Report: six-
fold faster absorption; FDA PK dataset
complete
‣ 6 OCT First ROXUS® prescriptions fulfilled in
the U.S.
‣ 21 OCT SPONTAN surpasses 2,000 dispensed
units under TGA’s Special Access Scheme
(SAS)
‣ 22 OCT SPONTAN Ethics Approval for
Pulmonary Arterial Hypertension (PAH)
Source: ASX announcements, July to October 2026. These events occurred after the end of FY26 (30 June 2026).
Q1 FY27
AGM Presentation | October 2026
Clinical proof established
‣ SPONTAN / ROXUS is a rapid-acting
intranasal PDE5 therapy. Final Phase II
data confirmed six-fold faster median
absorption than oral vardenafil
(p<0.0001), with a favourable safety
and tolerability profile.¹
‣ Lead program: SPONTAN / ROXUS
Executive Summary
5
Clinical validation → Real-world validation → U.S. prescriptions commenced
Footnotes: 1) Six-fold refers to median Tmax of 10 minutes for SPONTAN 5 mg versus 60 minutes for oral vardenafil 20 mg (p<0.0001); final Phase II Clinical Study Report,
ASX announcement 1 October 2026. 2) ASX announcement 11 August 2026. 3) Appendix 4C for quarter ended 30 June 2026. Cash figures in Australian Dollars.
1
6× faster
median absorption
Real-world demand validated
‣ A 147-patient Australian TGA SAS
cohort: 93% of men seeking greater
convenience and spontaneity reported
improved erectile hardness and/or
penetration (42 of 45); 68% across the
full cohort.²
‣ Evidence: clinical + patient reported
U.S. prescriptions commenced
‣ ROXUS patient-specific prescription
fulfilment commenced under Shed
and Strive (Oct 2026). The FDA
pharmacokinetic dataset is complete;
pivotal Phase III is targeted for
1H CY2027. $19.6M cash and zero
debt support near-term execution.³
‣ Commercial partners: Shed, Strive, Aptar, Mayne,
EBOS/Symbion
Response in men seeking
convenience (42 of 45)
Minimum ROXUS units Shed
has committed to support
2 3
AGM Presentation | October 2026
93% 150,000
Oral PDE5 inhibitors remain first-line, but response and persistence limitations leave a sizeable unmet need
~US$5B
estimated annual global
ED drug market¹
~322M
men globally estimated
to have ED in 2025¹
Treatment pathway and gap
Rapid-onset,
non-invasive PDE5 option
‣ Positioned across the broad ED market
‣ Supports patients seeking greater
spontaneity
‣ Provides a non-invasive option for
patients inadequately served by oral
therapy
‣ Positioned before invasive treatments
1) Frost & Sullivan, The Erectile Dysfunction Medicines Market, September 2023. 2) McMahon et al., BMJ 2006. 3) Gillman & Chung, ANZ Journal of Surgery 2026 (MBS data 1996–2024; in-
office, MBS-billed procedures only).
Large ED Market with a Clear Treatment Gap
Oral PDE5 inhibitors
First-line therapy; delayed onset
and high discontinuation
1
30–35% inadequate response
Higher failure rates in difficult-
to-treat populations²
2
Invasive second-line options
Intracavernosal injection utilisation
has fallen >55-fold from peak³
3
AGM Presentation | October 2026 6
30 to 120 minutes
to peak
Median Tmax: avanafil 30 min, sildenafil 60 min,
vardenafil 60 min, tadalafil 120 min.
Intimacy has to be planned around the tablet
Food, alcohol
and the gut
A high-fat meal delays and reduces absorption
of sildenafil and vardenafil. Dyspepsia and reflux
are common reasons men avoid daily dosing.
Timing rules add friction to an already
sensitive moment.
First-pass
metabolism
Oral PDE5is are absorbed through the gut and pass
through the liver, where 90 to 95% of the drug
is removed before it reaches the circulation.
Higher doses are needed to reach
therapeutic levels
Agent US brand Usual on-demand dose Route Median Tmax Half-life
Sildenafil Viagra® 25, 50, 100 mg Oral 60 min ~4 h
Vardenafil Levitra® 10, 20 mg Oral 60 min ~4 h
Tadalafil Cialis® 10, 20 mg (5 mg daily) Oral 120 min 17.5 h
Avanafil Stendra® 50, 100, 200 mg Oral 30 min ~5 h
Vardenafil ROXUS® 5 mg (2.5 mg per nostril) Intranasal 10 min ~4 h
PDE5 inhibitors work. Oral delivery is the constraint
Same mechanism; the difference is absorption speed
Sources: Wolfe TR. Not Just a Single Squirt: Understanding Nasal Drug Delivery. EMS Airway, 2022. US prescribing information for Viagra, Levitra, Cialis, Stendra.
Roxus Tmax: Chung et al. 2025; LTR Pharma Phase II final data, 1 October 2026. Half-lives approximate.
AGM Presentation | October 2026 7
Design agreed with FDA at Pre-IND. Final report completes the PK dataset for the planned 505(b)(2) submission.
Comparative PK results Six-fold faster absorption, p<0.0001
Parameter
5 mg 2.5 mg
Vardenafil
20 mg oral
Tmax, median (range) 10 min (10–15) 11 min (5–60) 60 min (30–186)
Cmax (mean ± SD, ng/mL) 8.9 ± 6.8 5.8 ± 4.9 19.8 ± 8.8
Half-life (t½, mean) 4.4 hours 3.8 hours 4.4 hours
Dose-normalised
AUC0-inf (ng·h/mL/mg)
3.6 4.8 3.2
Accumulation ratio
(5 days once daily)
1.0 ± 0.9 n.a. n.a.
SAEs / Grade 3+ TEAEs /
discontinuations
0 0 0
Final Phase II Report Confirms Six-Fold Faster Absorption
and Completes FDA PK Dataset
AGM Presentation | October 2026 8
Key Findings
‣ Six-fold faster absorption than oral vardenafil (p<0.0001)
‣ Approximately dose-proportional exposure;
substantially lower metabolite (M1) exposure than
the oral tablet
‣ No drug accumulation over five days of once-daily
dosing
‣ Comparable pharmacokinetics in men aged 65 and over
(14 of 27)
‣ No SAEs, no Grade 3+ events, no discontinuations;
most frequent treatment-related events nasal
congestion and headache, mild and self-resolving
Final Clinical Study Report | n=27 (14 aged ≥65) | randomised three-way crossover | independent CRO
Real-World Outcomes: Patient-Reported Response
9
93% men seeking greater convenience
and spontaneity (42 of 45) 68%overall cohort (100 of 147)
53% achieved penetration following
treatment (78 of 147)
Composite endpoint by subgroup By reason for seeking treatment and prostatectomy status
Inadequate response to oral PDE5 therapy
64% 56 of 87
Post-prostatectomy subgroup
73%
Non-prostatectomy subgroup
Post-prostatectomy context: oral PDE5i response 12–17% in the first six months²; ED in up to 85% of men¹
Source: ASX announcement 11 August 2026. 1) Emanu JC et al., Curr Opin Support Palliat Care 2016;10(1):102-107. 2) Published literature as cited in ASX announcement 11 August 2026. Disclosure: The study was supported
by an investigator-initiated grant from LTR Pharma. Melissa Hadley Barrett has a paid consulting role with LTR Pharma.
Improved erectile hardness and/or achieving penetration | 147 treatment-experienced men
Highest response among men seeking greater convenience and spontaneity, with encouraging
results in men inadequately served by oral therapy and men following prostatectomy.
44 of 60
AGM Presentation | October 2026
ROXUS® U.S. patient-specific prescription fulfilment has commenced.
ASX announcement 6 October 2026
ROXUS® U.S. Prescriptions Commenced
First valid patient-specific ROXUS® prescriptions fulfilled by Strive through Mavrox
ROXUS® is a compounded medication prepared for an identified individual patient on a valid prescription from a prescribing healthcare practitioner and, as such, is not reviewed or approved by the U.S. Food and Drug
Administration for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug.
Demand Engine
Shed Holdings LLC | Executed 17 Jul 2026
US direct-to-consumer telehealth platform: Mavrox
‣ First U.S. commercial route-to-market; first valid patient-specific prescriptions
received through Mavrox and fulfilled
‣ Committed to support a minimum of 150,000 ROXUS® units in the first 12
months from Commercial Launch, underpinning its telehealth exclusivity
‣ Two-year U.S. DTC telehealth exclusivity from launch, subject to performance
Supply Engine
Strive Pharmacy | Executed 20 Jul 2026
Exclusive US 503A pharmacy and fulfilment partner
‣ Five-state 503A platform with nationwide compounding and fulfilment
licensure
‣ Technology transfer and readiness complete; approximately 100,000 Aptar
pump and bottle components received
‣ Two-year exclusivity, subject to performance; LTR retains product ownership,
IP and formulation supply
‣ Moves ROXUS® from U.S. Market preparation
to prescription fulfilment
‣ Capital-light model using established telehealth
and pharmacy infrastructure
‣ First patient-specific prescriptions now being fulfilled
‣ Premium ED positioning without LTR building U.S.
prescribing, pharmacy or fulfilment infrastructure
AGM Presentation | October 2026 10
Portfolio Overview
and Development
Focus
11
Lead Clinical Program ‣ TGA Early Access – ACTIVE
‣ FDA 505(b)(2) regulatory pathway
‣ Phase II PK study complete; final report completes FDA PK
dataset
‣ U.S. ROXUS prescription fulfilment commenced (Oct 2026)
Early Development
OROFLOW – Platform Expansion
‣ HREC-approved study; initiation pending hospital contract
sign-off
‣ First platform application beyond ED, in gastrointestinal
disease
‣ Capital prioritised to lead program
Strategic Investment
LevOmega
‣ 43% equity interest
‣ Separate development pathway and capital structure; LTR
capital prioritised for core intranasal programs
Validated Platform
and Expanding Men’s
Health Portfolio
Intranasal Sprays for Erectile
Dysfunction
Intranasal Spray for
Oesophageal Motility Disorders (OMD)
Nature-Identical omega-3 Products
Portfolio Expansion
KYZATREX®
‣ Exclusive pilot commercialisation agreement with Marius
Pharmaceuticals (US)
‣ FDA-approved oral testosterone therapy; initial Australian
patient access via the TGA Special Access Scheme
‣ Six-month evaluation period, with a right to negotiate an
exclusive Australian licence
Oral Therapy for Testosterone
Deficiency
AGM Presentation | October 2026
Cash $19.6M | Avg. quarterly net operating outflow $2.8M¹ | Zero debt |
Funded to deliver near-term U.S. commercial, clinical and regulatory value inflection points
Key Milestones
AGM Presentation | October 2026 12
Completed milestones → current execution → next major value inflection points
‣ U.S. ROXUS® prescription fulfilment
commenced
‣ Final Phase II report completed FDA PK
dataset
‣ 147-patient real-world data reported
‣ Shed and Strive definitive U.S. agreements
executed
‣ FDA Pre-IND alignment
‣ Extractables study completed
‣ EJPS publication
‣ ROXUS® - U.S. prescription activity
– U.S. prescription activity building
following commencement
– Further updates as meaningful
information becomes available
‣ SPONTAN® - Phase III initiation / start-up
activities
– Post-Phase II FDA engagement and IND
preparation
– Site and study start-up activities
‣ SPONTAN® - Submission-enabling
workstreams
– CMC, human factors, leachables and non-
clinical toxicology
‣ OROFLOW® - Study initiation
– HREC approved
– Hospital contract sign-off pending
‣ ROXUS® - U.S. Commercial Scale-Up
– Growing U.S. prescription activity and
revenue contribution
‣ SPONTAN® - First patients enrolled in
pivotal Phase III - 1H CY2027
‣ SPONTAN® - Pivotal Phase III recruitment /
execution
‣ SPONTAN® - U.S. FDA submission
– Targeted 2H CY2027, subject to Phase III
completion and finalisation of the
submission package
‣ SPONTAN® - Pulmonary Arterial
Hypertension (PAH) – clinical results
‣ OROFLOW® - Initial clinical results
‣ SPONTAN® - U.S. licensing / commercial
partnering
COMPLETED
Achieved
EXECUTE NOW
CY2026 Near-Term Execution
NEXT INFLECTION
1H CY2027+ Development Progression
Source: Appendix 4C for the quarter ended 30 June 2026.1) Average net operating cash outflow per quarter over the twelve months to
30 June 2026. June 2026 quarter net operating outflow: $4.4M. Cash figures in Australian Dollars.
Making headlines
in FY26
Throughout FY26, LTR
Pharma’s clinical and
commercial milestones
were reported across
Australian business and
investor media, including
Stockhead, The Australian,
Ausbiz, Small Caps, and
biotech publications.
SPONTAN’s science reached clinicians directly
in FY26: published in the European Journal of
Pharmaceutical Sciences, delivered from the
podium at WMSM 2026 in Porto, Portugal, and
presented to urologists at APCC Sydney and
GPs nationally.
AGM Presentation | October 2026
Dr. JULIAN CHICK
(Independent Non-Executive Director)
▲ Over 20 years’ experience in senior
management and board positions,
including ASX-listed Avexa and
Admedus.
▲ CEO of ReNerve Ltd (ASX: RNV); director
of MABT Pty Ltd and LTR Medical Pty Ltd.
▲ Eight years’ investment banking
experience and a former analyst role
reviewing healthcare and biotechnology
investment opportunities for private
equity and venture capital investors.
▲ Chair of the Nomination and
Remuneration Committee.
Ms. MAJA MCGUIRE
(Independent Non-Executive Director)
▲ Over 15 years’ experience advising and
leading ASX-listed companies as an
Australian-qualified lawyer, spanning
non-executive chair and director roles,
general counsel and company secretary
positions, and top-tier private practice.
▲ Former executive roles with Anteris
Technologies (ASX: AVR) and Alexium
International (ASX: AJC).
▲ Director of ReNerve Ltd (ASX: RNV),
TechGen Metals Ltd (ASX: TG1) and
Kuniko Ltd (ASX: KNI).
▲ Chair of the Audit and Risk Committee.
Board of Directors
Seasoned leadership driving innovation and growth in healthcare
AGM Presentation | October 2026
Mr. LEE RODNE
(Executive Chairman)
▲ Healthcare entrepreneur and executive
with 25+ years’ experience building,
commercialising and scaling healthcare
and technology businesses across public
and private markets.
▲ Former CEO and Managing Director of
Allied Medical, a Fortescue Metals Group
spin-out (later Admedus Ltd, now Anteris
Technologies), which he led from an
approximately $800k valuation to a peak
valuation of approximately $250m.
▲ Track record commercialising medical
products across Australia, North
America, Europe and Asia, including
experience in nasal drug-delivery
products.
Executive Chairman | Lee Rodne
Over 25 years in healthcare and tech sectors in both public ASX and private
enterprises.
Chief Financial Officer | Jacques Schipper
Over 15 years of experience in finance, commercial management and controller roles.
Chief Operating Officer | Peter McLennan
Over 15 years of experience in investment banking, investor relations and operations.
Chief Medical Officer | Prof Geoffrey Strange
Over 20 years of experience in the pharmaceutical and medical industries as a senior
executive and medical researcher.
Chief Commercial Officer | Danny Zanardo
Over 25 years of commercial experience in the Australian and global healthcare
sectors across pharmaceuticals and medical devices.
Program Director | Anthony Bishop
Over 30 years of experience in all aspects of pharmaceutical, medical device and
diagnostic development for global markets.
Global Team, Strategic US Presence
General Manager & Business Development US | Tom Riester
Over 25 years of experience in sales and management in digital health, medical device and
precision medicine.
Vice President – US Sales & Marketing | Mike Sweeting
Over 30 years in the pharmaceutical industry in US commercial sales and market access.
Vice President Operations & Clinical Development | Dr Monil Shah
Over 20 years of pharmaceutical and biotechnology industry experience in drug
development.
Vice President, Global Regulatory Affairs | Kip Vought
Over 25 years across global markets - Senior Pharmaceutical R&D and regulatory executive.
Experienced leadership across key markets
US TEAM
AGM Presentation | October 2026
Executive Team
Corporate Snapshot
As of 22 October 2026
ASX code LTP
Shares on issue 182.27M
Market capitalisation $85.66M
Cash and cash equivalents (30 June 2026) A$19.6M
Debt Nil
Top 20 shareholders 45.73%
AGM Presentation | October 2026
Source: Appendix 4C for the quarter ended 30 June 2026.
Share your feedback
Discover